Individuals who were previously unable to tolerate elexacaftor–tezacaftor–ivacaftor were excluded. The patients were randomly assigned 1:1 to VTD or ETI for 52 weeks. The primary endpoint was absolute ...
Click to share on Facebook (Opens in new window) Click to share on X (Opens in new window) Click to email a link to a friend (Opens in new window) Click to share on LinkedIn (Opens in new window ...